New data announced for
Phase 2 Part A study in DME

Read the full press release


Business Update

2021 Full Year Results
and 2022 Outlook

To the press release


Tom Graney, CFA appointed CEO of Oxurion


Capital Commitment

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Read More


Our mission

To prevent vision loss and address unmet medical needs in retinal disorders

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Advancing Science. Enhancing Vision.

Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, our novel therapeutic for the treatment of DME.

We are committed to helping improve and preserve vision for patients with retinal disorders.

- Patrik De Haes, MD, Non-Executive Chairman of Oxurion



Oxurion employees are united by a shared goal: to make Oxurion a global leader in developing innovative treatments for retinal disorders including diabetic macular edema (DME). Want to join us?

Visit our careers site


Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe